| Titre | A Phase II Study of Darolutamide (ODM-201) in Patients with Metastatic Castration-Resistant Prostate Cancer Previously Treated with Abiraterone Acetate or Enzalutamide - A Sub-Study of IND.234 |
| Protocole ID | IND.234C |
| ClinicalTrials.gov ID | NCT03385655 |
| Type(s) de cancer | Prostate |
| Phase | Phase II |
| Médicament | Darolutamide (ODM-201) |
| Institution |
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
| Ville | Montréal |
| Investigateur(trice) principal(e) |
Dr Fred Saad |
| Coordonnateur(trice) |
Amal Nadiri 514-890-8000 poste 26074 |
| Statut |  Actif en recrutement |
| Critètes d'éligibilité |
Patients must meet the following criteria in addition to the eligiblity criteria outlined in IND.234.
|
| Critètes d'exclusion |
Groupe d'étude en oncologie du Québec